| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 350.81% | HC Wainwright & Co. | $11 → $8 | Reiterates | Buy → Buy |
| 03/15/2023 | 463.51% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 01/24/2023 | 519.86% | Morgan Stanley | $15 → $11 | Maintains | Overweight |
| 11/21/2022 | 463.51% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 11/30/2021 | 1083.37% | Morgan Stanley | → $21 | Initiates Coverage On | → Overweight |
| 11/30/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/30/2021 | 1027.01% | Jefferies | → $20 | Initiates Coverage On | → Buy |
What is the target price for IO Biotech (IOBT)?
The latest price target for IO Biotech (NASDAQ: IOBT) was reported by HC Wainwright & Co. on August 11, 2023. The analyst firm set a price target for $8.00 expecting IOBT to rise to within 12 months (a possible 350.81% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for IO Biotech (IOBT)?
The latest analyst rating for IO Biotech (NASDAQ: IOBT) was provided by HC Wainwright & Co., and IO Biotech reiterated their buy rating.
When is the next analyst rating going to be posted or updated for IO Biotech (IOBT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IO Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IO Biotech was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
Is the Analyst Rating IO Biotech (IOBT) correct?
While ratings are subjective and will change, the latest IO Biotech (IOBT) rating was a reiterated with a price target of $11.00 to $8.00. The current price IO Biotech (IOBT) is trading at is $1.77, which is out of the analyst's predicted range.